The Expression of P63 Marker in Malignant and Benign Breast Tumors
DOI:
https://doi.org/10.30750/ijpbr.11.2.04Keywords:
Cancer, Breast tumor, Diagnostic markers, Immunohistochemical.Abstract
This is retrospective study conducted on Sudanese patient in the period from January 2021 to May 2021 at radiation and isotope center Khartoum.
In this study we aimed to determine the expression of P63 marker in malignant and benign breast tumor.
One hundred paraffin embedded blocks previously diagnosed as breast tumors were collected.
The study including 65 (65%) samples of them were malignant and 35 (35%) samples of them were benign.
All these samples were Immunohistochemically stained by using monoclonal antibodies (by indirect streptavidin-biotin technique) for p63.
All immune stained slides were scored as either positive or negative.
Data collected from patient file and result were analyzed using social science statistic web SPSS computer program.
References
Afonso, N., & Bouwman, D. (2008). Lobular carcinoma in situ. European Journal of Cancer Prevention, 17(4), 312-316. Al-Joudi, F. S., Iskandar, A. Z., Hasnan, J., Rusli, J., Kamal, Y., Imran, A. K., ... & Zakaria, J. (2007). Expression of p63 and its clinicopathological correlations in invasive ductal carcinoma of the breast. Singapore medical journal, 48(7), 607. Alfredo, R., Garcia, S. B., Ribeiro, S., & Zucoloto, S. (2003). The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Archives of pathology & laboratory medicine, 127(3), 336-340. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, Hirunpat S, Woodtichartpreecha P, Boonlikit S, Teerawattananon Y, Thakkinstian A (2013). "Risk factors of breast cancer: a systematic review and meta-analysis". Asian Pacific Journal of Public Health. 25 (5): 368–387. Autier, P. (2012). Risk factors for breast cancer for women aged 40 to 49 years. Ann Intern Med, 157(7), 529. Bancroft, J. D., Floyd, A. D., & Suvarna, S. K. (2013). Bancroft\'s Theory and Practice of Histological Techniques. Berg, W. A., Madsen, K. S., Schilling, K., Tartar, M., Pisano, E. D., Larsen, L. H., & Kalinyak, J. E. (2011). Breast cancer: comparative effectiveness of 29 positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology, 258(1), 59-72 Bilal, H., Handra-Luca, A., Bertrand, J. C., & Fouret, P. J. (2003). P63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues. Journal of Histochemistry & Cytochemistry, 51(2), 133-139. Böhm, I. (2011). Breast cancer in lupus. The Breast, 20(3), 288-290. Boris P (2010). Cancer Genetics (Cancer Treatment and Research). Berlin: Springer. 1 th ed. vol (155) pp: 19–20. Carta, A., Chetcuti, R., & Ayers, D. (2014). An introspective update on the influence of miRNAs in breast carcinoma and neuroblastoma chemoresistance. Genetics research international. Colditz, G. A., Kaphingst, K. A., Hankinson, S. E., & Rosner, B. (2012). Family history and risk of breast cancer: nurses’ health study. Breast cancer research and treatment, 133(3), 1097-1104. Collaborative Group on Hormonal Factors in Breast Cancer. (2001). Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. The Lancet, 358(9291), 1389-1399. Dusek, R. L., Bascom, J. L., Vogel, H., Baron, S., Borowsky, A. D., Bissell, M. J., & Attardi, L. D. (2012). Deficiency of the p53/p63 target Perp alters 31 mammary gland homeostasis and promotes cancer. Breast Cancer Research, 14(2), R65. Eheman, C. R., Shaw, K. M., Ryerson, A. B., Miller, J. W., Ajani, U. A., & White, M. C. (2009). The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. Cancer Epidemiology and Prevention Biomarkers, 18(6), 1763-1769. Gage M, Wattendorf D, Henry LR (2012). "Translational advances regarding hereditary breast cancer syndromes". Journal of surgical oncology. 105 (5): 444–51. Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S.,Crews, J. R., Davidson, N. E., & Lin, N. U. (2014). Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 32(19), 2078-2099. Guray, M., & Sahin, A. A. (2006). Benign breast diseases: classification, diagnosis, and management. The oncologist, 11(5), 435-449. Henderson, B. E., & Bernstein, L. (1991). The international variation in breast cancer rates: an epidemiological assessment. Breast cancer research and treatment, 18(1), S11-S17. Inoue, K., & Fry, E. A. (2014). Alterations of p63 and p73 in human cancers.: Mutant p53 and MDM2 in Cancer (85) 17-40. 31 Intisar, E S., Hsin, W., Kamal, H M., Sulma, I M. (2014). Cancer incidence in Khartoum Sudan: first results from the Cancer Registry (2009-2010). Cancer Medicine 3(4): 1075–1084. Jahanzeb, M. (2008). Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clinical breast cancer, 8(4), 324-333. Johnson, R. E., & Murad, M. H. (2009). Gynecomastia: pathophysiology, evaluation, and management. In Mayo Clinic Proceedings, 84 (11), 1010- 1015. Kabel, A. M. (2017). Tumor markers of breast cancer: New prospectives. Journal of Oncological Sciences, 3(1), 5-11. Kabel, A. M., El-Rashidy, M. A., & Omar, M. S. (2016). Ameliorative Potential of Tamoxifen/Thymoquinone Combination in Patients with Breast Cancer: A Biochemical and Immunohistochemical Study. Journal of cancer science and research, 1(102), 2. Kennedy, P. (2003). A guide to econometrics.4 th ed. MIT press. Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., & Davidson, N. E. (2006). American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. Journal of Clinical Oncology, 24(31), 5091-5097. 32 Kinoshita, T., Yashiro, N., Yoshigi, J., Ihara, N., & Narita, M. (2002). Fat necrosis of breast: a potential pitfall in breast MRI. Clinical imaging, 26(4), 250-253. Lee, A., Arteaga, C., & Smith, I. (2009). 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium. Journal of medical and dental science research. 4 (5): 21-30. Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2002). Changing incidence of lobular carcinoma in situ of the breast. Breast cancer research and treatment, 75(3), 259-268. Liberman, L., Bracero, N., Morris, E., Thornton, C., & Dershaw, D. D. (2005). MRI-guided 9-gauge vacuum-assisted breast biopsy: initial clinical experience. American Journal of Roentgenology, 185(1), 183-193. Lopes, L. V., Miguel, F., Freitas, H., Tavares, A., Pangui, S., Castro, C., & Santos, L. L. (2015). Stage at presentation of breast cancer in Luanda, Angola-a retrospective study. BMC health services research, 15(1), 471. MaricP., Ozretić, P., Levanat, S., Orešković, S., Antunac, K., & BeketićOrešković, L. (2011). Tumor markers in breast cancer–evaluation of their clinical usefulness. Collegium antropologicum, 35(1), 241-247. Mathes, S. J., & Nahai, F. (1997). Reconstructive surgery: principles, anatomy & technique (Vol. 1). Churchill Livingstone. Maxwell, G. P., & Gabriel, A. (2009). Breast reconstruction. Aston SJ, Steinbrech DS, Walden JL. Aesthetic Plastic Surgery. 33 McPherson, K., Steel, C. and Dixon, J M. (2000). Breast cancer— epidemiology, risk factors, and genetics. British Medical Journal, 321(7261): 624-628. McPherson, K., Steel, C., & Dixon, J. M. (2000). ABC of breast diseases: breast cancer—epidemiology, risk factors, and genetics. British Medical Journal, 321(7261), 624. Mohammed, Z. M., Going, J. J., Edwards, J., Elsberger, B., Doughty, J. C., & McMillan, D. C. (2012). The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. British journal of cancer, 107(5), 864. Narula, H. S., & Carlson, H. E. (2014). Gynaecomastia—pathophysiology, diagnosis and treatment. Nature Reviews Endocrinology, 10(11), 684. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, Miglioretti DL (2012). "Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis". Annals of Internal Medicine. 156 (9): 635–48. Newcomer, L. N. (2012). Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. Health Affairs, 31(4), 780-785. Niewoehner, C. B., & Schorer, A. E. (2008). Gynaecomastia and breast cancer in men. British Medical Journal, 336(7646), 709. 34 Park, C. K., & Oh, Y. H. (2005). Expression of p63 in reactive hyperplasias and malignant lymphomas. Journal of Korean medical science, 20(5), 752- 758. Rack, B., Schindlbeck, C., Jueckstock, J., Genss, E. M., Hepp, P., Lorenz, R.,& Sommer, H. (2010). Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. Anticancer research, 30(5), 1837-1841. Rosai J, (2004). Breast. In: Rosai and Ackerman’s Surgical Pathology ,9 th ed.: Mosby,1763–1876. Sang X, Oni, A. A., & LeBeau, J. M. (2014). Atom column indexing: atomic resolution image analysis through a matrix representation. Microscopy and Microanalysis, 20(6), 1764-1771. Saslow D, Hannan J, Osuch J, Alciati MH, Baines C, Barton M, Bobo JK, Coleman C, Dolan M, Gaumer G, Kopans D, Kutner S, Lane DS, Lawson H, Meissner H, Moorman C, Pennypacker H, Pierce P, Sciandra E, Smith R, Coates R (2004). "Clinical breast examination: practical recommendations for optimizing performance and reporting". CA: A Cancer Journal for Clinicians. 54 (6): 327–344. Saunders, C; Jassal, S (2009). Breast cancer (1st ed.). Oxford: Oxford University Press. p. Chapter 13. 35 Shah R., Rosso, K., & Nathanson, S. D. (2014). Pathogenesis, prevention, diagnosis, and treatment of breast cancer. World journal of clinical oncology, 5(3), 283. Shao, Y., Sun, X., He, Y., Liu, C., & Liu, H. (2015). Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PloS one, 10(7), e0133830. Shih Ie, M., and R. J. Kurman (2004). "p63 expression is useful in the d istinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations." American Journal Surgical Pathology 28(9): 1177-83. Shulman, D. I., Francis, G. L., Palmert, M. R., & Eugster, E. A. (2008). Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics, 121(4), e975-e983. Siegel, R., Ward, E., Brawley, O., & Jemal, A. (2011). Cancer statistics: a cancer journal for clinicians, 61(4), 212-236. Singletary, S. E. (2003). Rating the risk factors for breast cancer. Annals of surgery, 237(4), 474. Sinn, H. P., & Kreipe, H. (2013). A brief overview of the WHO classification of breast tumors. Breast Care, 8(2), 149-154. Stefanou, D., Batistatou, A., Nonni, A., Arkoumani, E., & Agnantis, N. J. (2004). p63 expression in benign and malignant breast lesions. Histology and histopathology, 19(2), 465-472. 36 Traum,A. Z, Wells ,M. P, Aivado, M., libermann , T.A, Ramoni ,M. F. and Schachter , A. D .(2006) SELDI-TOF MS of quadruplicate urine and serum samples to evaluate change related to storage condition . proteomics 6,1676- 1680. Varga, Z., & Mallon, E. (2009). Histology and immunophenotype of invasive lobular breast cancer. daily practice and pitfalls. Breast disease, 30(1), 15-19. Virnig, B. A., Shamliyan, T., Tuttle, T. M., Kane, R. L., & Wilt, T. J. (2009). Diagnosis and management of ductal carcinoma in situ (DCIS). Evidence report/technology assessment, (185), 1-549. You, W., & Henneberg, M. (2018). Cancer incidence increasing globally: The role of relaxed natural selection. Evolutionary applications, 11(2), 140-152. Yu YH, Liang C, Yuan XZ (2010). "Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review". Breast cancer research and treatment. 120 (2): 469–79.
Downloads
Published
2023-07-27
How to Cite
1.
Mirghani RH, Abdallah KA, Badawi MI, Abdulraoof N, Abdumalik R. The Expression of P63 Marker in Malignant and Benign Breast Tumors. IJPBR [Internet]. 2023Jul.27 [cited 2026Jul.14];11(02):16-9. Available from: https://ijpbr.in/index.php/IJPBR/article/view/1029
Issue
Section
Review Article
